1268454-23-4

Basic information

• Product Name: INK1117
• Synonyms: Methanone, [6-(2-aMino-5-benzoxazolyl)iMidazo[1,2-a]pyridin-3-yl]-4-Morpholinyl-;INK-1117 MLN1117;MLN1117;MLN1117 (INK1117);TAK-117(INK1117,MLN1117);[6-(2-Amino-5-benzoxazolyl)imidazo[1,2-a]pyridin-3-yl]-4-morpholinylmethanone;[6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone;methyl 6-((5-((3-(trifluoromethyl)phenyl)carbamoyl)naphthalen-2-yl)oxy)pyrimidine-4-carboxylate
• CAS NO: 1268454-23-4
• Molecular Formula: C19H17N5O3
• Molecular Weight: 363.36998
• Mol File: 1268454-23-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• Solubility: ≤1mg/ml in DMSO;0.25mg/ml in dimethyl formamide
• PKA: 4.75±0.50(Predicted)
• CAS DataBase Reference: INK1117(CAS DataBase Reference)
• NIST Chemistry Reference: INK1117(1268454-23-4)
• EPA Substance Registry System: INK1117(1268454-23-4)

Safety Data

• Hazardous Substances Data: 1268454-23-4(Hazardous Substances Data)

Usage

Description

INK1117, also known as MLN1117, is a selective inhibitor of phosphoinositide 3-kinase α (PI3Kα) that targets the p110α subunit in vitro with high specificity (IC50 = 15 nM for PI3Kα vs. >1 μM for other isoforms, as well as for mTOR). It effectively blocks signaling to Akt and inhibits the growth of cancer cells with wild-type or mutated p110α without interfering with B cell proliferation or NK cell maturation and survival.

Uses

Used in Pharmaceutical Industry:
INK1117 is used as a PI3Kα inhibitor for the attenuation of cell proliferation, particularly in cancer cells with wild-type or mutated p110α. Its high selectivity and specificity make it a valuable tool in the development of targeted cancer therapies.
Used in Cancer Research:
INK1117 is used as a research compound to study the role of PI3Kα in various cellular processes, including cell growth and proliferation. It can be employed to investigate the underlying mechanisms of cancer development and progression, as well as to identify potential therapeutic targets for cancer treatment.
Used in Drug Development:
INK1117 serves as a lead compound in the development of novel drugs targeting the PI3Kα pathway. Its selective inhibition of p110α can be leveraged to design more effective and less toxic cancer treatments, potentially improving patient outcomes and quality of life.
Used in Cell Signaling Studies:
INK1117 is used as a molecular probe to investigate the signaling pathways involving PI3Kα and its downstream effector, Akt. Understanding these pathways can provide insights into the regulation of cellular processes and the development of targeted therapies for various diseases, including cancer.
Used in Preclinical Models:
INK1117 is used in preclinical models to evaluate its efficacy and safety as a potential therapeutic agent for cancer treatment. These studies can help determine the optimal dosing, administration, and potential side effects of INK1117, paving the way for its progression to clinical trials and eventual use in patients.

Biological Activity

ink1117 is a novel, potent and selective inhibitor of pi3kα with potential antineoplastic activity, which may induce tumor cell apoptosis and growth inhibition in pi3kα-expressing tumor cells. ink1117 dampens signaling to akt and suppresses the growth of cancer cells harboring wild-type or mutated p110α. pi3ks, a family of eight lipid kinase enzymes, produce 3-phosphorylated phosphoinositides in cellular membranes and are promising targets for therapeutic development in cancer.

in vitro

ink1117 blocked class i pi3k enzymes (p110α, p110β, p110γ or p110δ) in the low to mid-nanomolar range in human natural killer (nk) cell lines. ink1117 selectively inhibited pi3k signaling in cellular assays when used at 0.1-1 μm. ink1117 selectively dampened p110 α when used at 1 μm. ink1117 did not inhibit production of ifn-γ protein in cells with anti-nkg2d, indicating that ink1117 did not decrease ifn-γ mrna [1].

in vivo

female c57bl/6 mice were orally given ink1117 at a dose of 60 mg/kg using a sterile disposable 20g-1.5” feeding needle. after 8 days, ink1117 had negligible effects on nk cell maturation or survival. however, ink1117 did not show significantly decrease in the percentage of b cells and did not alter the percentages of t cells or the fractions of cd4 and cd8 t cells, the percentages of nk cells in bone marrow and spleen [1].

IC 50

15nm: inhibits phosphoinositide 3-kinase α (pi3kα) in vitro.

references

[1]. yea, s., so, l., mallya, s., lee, j., rajasekaran, k., malarkannan, s., & fruman, d. effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. plos one. 2014; 9(6): e99486.

Upstream product

• 1224844-66-9 5-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine 
• 64037-07-6 5-bromo-1,3-benzoxazol-2-amine 
• 40925-68-6 2-amino-4-bromo-phenol 
• 1404480-15-4 2-amino-benzooxazole-5-boronic acid hydrochloride 
• 1434089-03-8 C₁₂H₁₂BrN₃O₂ 
• 944896-42-8 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid 
• 372198-69-1 ethyl 6-bromoimidazol[1,2-a]pyridine-3-carboxylate 

Relevant articles and documents

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.